Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT04798430

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04798430
Other papers using this trial's data
  • Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial JAMA cardiology, 2026-06-01 DOI, PubMed 42054033, PMC13130062 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, India, Israel, Norway, South Africa, Türkiye (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04798430. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-03 (actual); primary completion 2025-07-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
Acronym
LIBerate-OLE
Condition
Cardiovascular Disease With Mention of Arteriosclerosis
Condition
Elevated Cholesterol
Intervention (Drug)
lerodalcibep
Lead sponsor
LIB Therapeutics LLC (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04798430
Content hash
3104b60797b0a0ffad04bf1626ee1f4e422e45ab159e63c26c5c52654dc538dc